Cargando…
Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 random...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454464/ https://www.ncbi.nlm.nih.gov/pubmed/34557402 http://dx.doi.org/10.3389/fonc.2021.638757 |
_version_ | 1784570497263992832 |
---|---|
author | Qin, Wei Fu, Di Shi, Qing Dong, Lei Yi, Hongmei Huang, Hengye Jiang, Xufeng Song, Qi Liu, Zhenhua Cheng, Shu Huang, Jinyan Wang, Li Xu, Pengpeng Zhao, Weili |
author_facet | Qin, Wei Fu, Di Shi, Qing Dong, Lei Yi, Hongmei Huang, Hengye Jiang, Xufeng Song, Qi Liu, Zhenhua Cheng, Shu Huang, Jinyan Wang, Li Xu, Pengpeng Zhao, Weili |
author_sort | Qin, Wei |
collection | PubMed |
description | The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 randomized trial NHL-001 (NCT01852435) were reviewed. Meanwhile, genetic aberrations, gene expression pattern, and tumor immunophenotype profile were revealed by DNA and RNA sequencing of 116 and 53 patients, respectively. SE patients showed similar clinicopathological features as SN patients, except for an increased percentage of low-intermediate risk in the National Comprehensive Cancer Network–International Prognostic Index. According to the molecular features, increased MPEG1 mutations were observed in SN patients, while SE patients were associated with upregulation of TGF-β signaling pathway and downregulation of T-cell receptor signaling pathway. SE patients also presented immunosuppressive status with lower activity of killing of cancer cells and recruiting dendritic cells. Extranodal involvement had no influence on progression-free survival (PFS) or overall survival (OS) in localized DLBCL. Serum lactate dehydrogenase >3 upper limit of normal was an independent adverse prognostic factor for OS, and ATM mutations were related to inferior PFS. Although the overall prognosis is satisfactory, specific clinical, genetic, and microenvironmental factors should be considered for future personalized treatment in localized DLBCL. |
format | Online Article Text |
id | pubmed-8454464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84544642021-09-22 Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma Qin, Wei Fu, Di Shi, Qing Dong, Lei Yi, Hongmei Huang, Hengye Jiang, Xufeng Song, Qi Liu, Zhenhua Cheng, Shu Huang, Jinyan Wang, Li Xu, Pengpeng Zhao, Weili Front Oncol Oncology The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 randomized trial NHL-001 (NCT01852435) were reviewed. Meanwhile, genetic aberrations, gene expression pattern, and tumor immunophenotype profile were revealed by DNA and RNA sequencing of 116 and 53 patients, respectively. SE patients showed similar clinicopathological features as SN patients, except for an increased percentage of low-intermediate risk in the National Comprehensive Cancer Network–International Prognostic Index. According to the molecular features, increased MPEG1 mutations were observed in SN patients, while SE patients were associated with upregulation of TGF-β signaling pathway and downregulation of T-cell receptor signaling pathway. SE patients also presented immunosuppressive status with lower activity of killing of cancer cells and recruiting dendritic cells. Extranodal involvement had no influence on progression-free survival (PFS) or overall survival (OS) in localized DLBCL. Serum lactate dehydrogenase >3 upper limit of normal was an independent adverse prognostic factor for OS, and ATM mutations were related to inferior PFS. Although the overall prognosis is satisfactory, specific clinical, genetic, and microenvironmental factors should be considered for future personalized treatment in localized DLBCL. Frontiers Media S.A. 2021-09-07 /pmc/articles/PMC8454464/ /pubmed/34557402 http://dx.doi.org/10.3389/fonc.2021.638757 Text en Copyright © 2021 Qin, Fu, Shi, Dong, Yi, Huang, Jiang, Song, Liu, Cheng, Huang, Wang, Xu and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qin, Wei Fu, Di Shi, Qing Dong, Lei Yi, Hongmei Huang, Hengye Jiang, Xufeng Song, Qi Liu, Zhenhua Cheng, Shu Huang, Jinyan Wang, Li Xu, Pengpeng Zhao, Weili Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title | Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title_full | Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title_fullStr | Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title_full_unstemmed | Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title_short | Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma |
title_sort | molecular heterogeneity in localized diffuse large b-cell lymphoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454464/ https://www.ncbi.nlm.nih.gov/pubmed/34557402 http://dx.doi.org/10.3389/fonc.2021.638757 |
work_keys_str_mv | AT qinwei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT fudi molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT shiqing molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT donglei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT yihongmei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT huanghengye molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT jiangxufeng molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT songqi molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT liuzhenhua molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT chengshu molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT huangjinyan molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT wangli molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT xupengpeng molecularheterogeneityinlocalizeddiffuselargebcelllymphoma AT zhaoweili molecularheterogeneityinlocalizeddiffuselargebcelllymphoma |